Short answer
Mirum Pharmaceuticals, Inc. (MIRM) filed its Q1 2026 10-Q quarterly report on May 6, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $160M (up 43.3% year over year) with net income of −$790M.
Q1 2026 key financials · XBRL
- Revenue
- $160M
- +43.3% YoY
- Net income
- −$790M
- −5283.6% YoY
- Operating margin
- -493.8%
- EPS (diluted)
- −$13.43
- −4376.7% YoY
Source: XBRL data from the Mirum Pharmaceuticals, Inc. (MIRM) Q1 2026 10-Q on SEC EDGAR. USD.
Mirum Pharmaceuticals, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Product revenue $159.9M, up $48.3M YoY from $111.6M
- Livmarli revenue $113.8M, up $40.6M; Bile Acid Medicines $46.1M, up $7.7M
- Operating margin -493.8% vs -13.6% YoY; net loss $790.2M vs $14.7M
- Cash, equivalents and investments $420.6M vs $391.4M at December 31, 2025
- Outlook: continued annual sales growth but quarterly volatility from Takeda and distributor orders; ongoing net losses expected
Risk Factors
- No newly added risk factor identifiable because the provided excerpt is truncated and lacks comparison with the prior 10-K
- EU Health Technology Assessment Regulation entered phased application January 12, 2025, expanding to orphan medicines in January 2028
- Medicaid rebate compliance exposure increased after the rebate cap elimination effective January 1, 2024
- Volixibat diarrhea incidence reached 77% in PBC VANTAGE and 40% versus 9% placebo in PSC VISTAS
- Commercial performance remains sensitive to payer restrictions, rebates, prior authorization, and Medicare drug-price negotiations
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Mirum Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.